Alvotech (ALVO)vsTakeda Pharmaceutical Co Ltd ADR (TAK)
ALVO
Alvotech
$3.54
-5.35%
HEALTHCARE · Cap: $1.05B
TAK
Takeda Pharmaceutical Co Ltd ADR
$15.60
+0.97%
HEALTHCARE · Cap: $49.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Takeda Pharmaceutical Co Ltd ADR generates 801568% more annual revenue ($4.51T vs $562.04M). TAK leads profitability with a 4.3% profit margin vs -14.4%. ALVO trades at a lower P/E of 33.6x. TAK earns a higher WallStSmart Score of 57/100 (C).
ALVO
Avoid21
out of 100
Grade: F
TAK
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+80.2%
Fair Value
$24.48
Current Price
$3.54
$20.94 discount
Intrinsic value data unavailable for TAK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Growing faster than its price suggests
Reasonable price relative to book value
Earnings expanding 330.2% YoY
Areas to Watch
Premium valuation, high expectations priced in
Smaller company, higher risk/reward
ROE of 0.0% — below average capital efficiency
Weak financial health signals
3.9% revenue growth
ROE of 2.5% — below average capital efficiency
4.3% margin — thin
Operating margin of 3.1%
Comparative Analysis Report
WallStSmart ResearchBull Case : ALVO
The strongest argument for ALVO centers on Debt/Equity.
Bull Case : TAK
The strongest argument for TAK centers on PEG Ratio, Price/Book, EPS Growth. PEG of 0.40 suggests the stock is reasonably priced for its growth.
Bear Case : ALVO
The primary concerns for ALVO are P/E Ratio, Market Cap, Return on Equity.
Bear Case : TAK
The primary concerns for TAK are Revenue Growth, Return on Equity, Profit Margin. A P/E of 42.5x leaves little room for execution misses. Thin 4.3% margins leave little buffer for downturns.
Key Dynamics to Monitor
ALVO profiles as a turnaround stock while TAK is a value play — different risk/reward profiles.
ALVO carries more volatility with a beta of 0.21 — expect wider price swings.
TAK is growing revenue faster at 3.9% — sustainability is the question.
ALVO generates stronger free cash flow (-68M), providing more financial flexibility.
Bottom Line
TAK scores higher overall (57/100 vs 21/100). ALVO offers better value entry with a 80.2% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Alvotech
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Alvotech Holdings SA, develops and manufactures biosimilars for global markets. The company is headquartered in Iceland.
Visit Website →Takeda Pharmaceutical Co Ltd ADR
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Takeda Pharmaceutical Company Limited is engaged in the research, development, manufacture and marketing of pharmaceuticals, over-the-counter drugs and quasi-drug consumer products, and other health care products. The company is headquartered in Tokyo, Japan.
Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?